Global Healthcare Testing Services Market, by Service Type (Chemical Testing, Microbiological Testing, Toxicology Testing, Stability Testing, and Others), by Product Type (Anti-viral Drugs, HIV Drugs, Fertility Drugs, Anti-diabetic Drugs, Respiratory Drugs, Anticoagulants, Medical Devices, Pharmaceutical Packaging, and Others), by Development Stage (Preclinical, Clinical, and Manufacturing), by End User (Pharmaceutical Industry, Contract Research Organization, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 5430.2 million in 2021 and is expected to exhibit a CAGR of 5.1% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.
Several pharmaceutical service providers are engaged in gaining license for expanding their testing services and to offer better products and healthcare testing services in the global healthcare testing services market is expected to drive the market growth over the forecast period.
For instance, in February 2020, ZYUS Life Sciences Inc., a Canada-based biotechnology company, received analytical testing license and research license from Health Canada, which further enables the development, production, clinical studies, and sales of medical cannabinoid-based formulation for offering advanced therapy for patients. With the license, the company’s laboratory is authorized to perform in-house analytical testing on cannabis and its derivative products.
Global Healthcare Testing Services Market – Impact of Coronavirus (Covid-19) Pandemic
COVID-19 outbreak was first reported on December 31, 2019, in Wuhan, China. According to the Coronavirus (COVID-19), Weekly Epidemiological Update by the World Health Organization, over 262,178,403 cases and 5,215,745 deaths due to Coronavirus (COVID-19) were reported up till November 30, 2021, across the globe.
The COVID-19 pandemic has negatively affected several markets across the globe and is also expected to have significant impact on the demand and supply in the global healthcare testing services market, owing to reduced access to services during the COVID-19 outbreak and nationwide lockdown. Since the outbreak of COVID-19 epidemic, prevention and treatment services for non-communicable diseases have been severely interrupted. Several people requiring treatment for ailments such as cancer, cardiovascular disease, and diabetes have been unable to access the health services and medications.